Pfizer’s Viracept Will Stay On The Market Despite Traces Of Carcinogen EMS
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer and FDA have agreed to specifications limiting EMS in the HIV drug, allowing it to remain on the market, according to the company.